Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Mikhail Kosiborod, Mark C. Petrie, Barry A. Borlaug, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 15, pp. 1394-1407
Closed Access | Times Cited: 187

Showing 1-25 of 187 citing articles:

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Javed Butler, Sanjiv J. Shah, Mark C. Petrie, et al.
The Lancet (2024) Vol. 403, Iss. 10437, pp. 1635-1648
Open Access | Times Cited: 125
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Milton Packer, Michael R. Zile, Christopher M. Kramer, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 88
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail Kosiborod, John Deanfield, Richard Pratley, et al.
The Lancet (2024) Vol. 404, Iss. 10456, pp. 949-961
Closed Access | Times Cited: 47
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
John Deanfield, Subodh Verma, Benjamin M. Scirica, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 773-786
Open Access | Times Cited: 43
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Heart Journal (2024)
Open Access | Times Cited: 41
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 39
2024 update in heart failure
Alberto Beghini, Antonio Maria Sammartino, Z. Papp, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 31
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
Sanjiv J Shah, Kavita Sharma, Barry A. Borlaug, et al.
European Heart Journal (2024) Vol. 45, Iss. 35, pp. 3254-3269
Open Access | Times Cited: 30
Semaglutide and NT-proBNP in Obesity-Related HFpEF
Mark C. Petrie, Barry A. Borlaug, Javed Butler, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 1, pp. 27-40
Open Access | Times Cited: 24
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure
Scott D. Solomon, John W. Ostrominski, Xiaowen Wang, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1587-1602
Open Access | Times Cited: 23
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 22
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Richard E. Pratley, Katherine R. Tuttle, Peter Rossing, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1615-1628
Open Access | Times Cited: 22
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S207-S238
Closed Access | Times Cited: 22
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction
Morten Schou, Mark C. Petrie, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 3, pp. 247-257
Open Access | Times Cited: 19
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction
Subodh Verma, Javed Butler, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 9, pp. 773-785
Open Access | Times Cited: 18
Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials
Frederick Berro Rivera, Linnaeus Louisse A. Cruz, John Vincent Magalong, et al.
American Journal of Preventive Cardiology (2024) Vol. 18, pp. 100679-100679
Open Access | Times Cited: 16
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Journal of Preventive Cardiology (2024)
Open Access | Times Cited: 16
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S167-S180
Closed Access | Times Cited: 16
Inflammation in Obesity-Related HFpEF
Subodh Verma, Mark C. Petrie, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1646-1662
Open Access | Times Cited: 15
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 6
Heart Failure with Preserved Ejection Fraction
Antonio Cannatà, Theresa A. McDonagh
New England Journal of Medicine (2025) Vol. 392, Iss. 2, pp. 173-184
Closed Access | Times Cited: 4
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
Nikolaos Theodorakis, Maria Nikolaou
Biomolecules (2025) Vol. 15, Iss. 2, pp. 213-213
Open Access | Times Cited: 4
Proteomic changes upon treatment with semaglutide in individuals with obesity
Lasse Maretty, Dipender Gill, Lotte Simonsen, et al.
Nature Medicine (2025)
Open Access | Times Cited: 2
Unlocking Therapeutic Potential for Cardiac Remodeling in Obesity-Related HFpEF
Khurram Nasir, Carlos Eduardo Rochitte
Journal of the American College of Cardiology (2025)
Closed Access | Times Cited: 2
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?
Paschalis Karakasis, Nikolaos Fragakis, Dimitrios Patoulias, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2112-2112
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top